Andrew Callos - 15 Mar 2026 Form 4 Insider Report for CYTOKINETICS INC (CYTK)

Reporting relationship: EVP, Chief Commercial Officer
Issuer ticker: CYTK
Reported as of: 15 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2026, 16:08:05 UTC
Prior SEC filing: 10 Mar 2026
Next SEC filing: 16 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John O. Faurescu, attorney-in-fact for Mr. Callos

Key filing fact

Andrew Callos filed Form 4 for CYTOKINETICS INC (CYTK) on 17 Mar 2026.

Key facts

This page summarizes Andrew Callos's Form 4 filing for CYTOKINETICS INC (CYTK).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 16:08.

Change

Previous filing in this sequence was filed on 10 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001852129 Primary reporting owner

Callos Andrew

Relationship: EVP, Chief Commercial Officer
Address: 350 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
Signature: /s/ John O. Faurescu, attorney-in-fact for Mr. Callos
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYTK transaction

Common Stock

Award

Transaction value
Shares: +20,646
Change %: +43%
Price: $0.000000^*
Shares after: 68,504
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1

CYTK transaction

Common Stock

Award

Transaction value
Shares: +13,320
Change %: +19%
Price: $0.000000^*
Shares after: 81,824
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYTK transaction Derivative

Incentive Stock Option (Right to Buy)

Award

Transaction value
Shares: +1,665
Change %
Price: $0.000000^*
Shares after: 1,665
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,665
Exercise price: $60.06
Footnotes: F3

CYTK transaction Derivative

Non-Qualified Stock Option (Right to Buy)

Award

Transaction value
Shares: +29,480
Change %
Price: $0.000000^*
Shares after: 29,480
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,480
Exercise price: $60.06
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

Footnote F2

Special supplemental equity award comprised of restricted stock units ("RSUs" that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 50% of the RSUs on the 1-year anniversary of the grant date and 50% of the RSUs on the 2-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

Footnote F3

Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

Footnote F4